CAREERS-LFB-USA.ICIMS.COM

lfb-usa.com

News Releases | LFB

http://lfb-usa.com/news

Bringing bioinnovation to patients. For US Residents Only. Message from the President. LFB SA.'s Pipeline. Framingham Biopharma Preps for Preeclampsia Market in Marlborough Expansion. Worcester Business Journal - July 16, 2015. Framingham biopharmaceutical firm LFB USA has pinned plans to build a new 65,000-square-foot manufacturing and laboratory facility in Marlborough in part on the expectation that its drug, ATryn, will soon receive FDA approval for the treatment of preeclampsia. LFB SA. Announce...

lfb-usa.com

Message from the President | LFB

http://lfb-usa.com/message-president

Bringing bioinnovation to patients. For US Residents Only. Message from the President. LFB SA.'s Pipeline. Message from the President. Message from the President. Our proprietary rPRO Technology allows the scalable and cost-effective production of recombinant proteins for a broad array of medical applications. This is evident by the regulatory (FDA and EMA) approval of ATryn. Looking forward, we will continue to demonstrate the value of LFB USA as a developer in our own right and as a reliable partner&#4...

revobiologics.com

Pipeline | rEVO

http://revobiologics.com/pipeline

For US Residents Only. Message from our President. The rEVO Biologics pipeline is focused on meeting the needs of under-served patient populations through innovative recombinant protein therapies. Click the graphic to enlarge. ATryn is a registered trademark of rEVO Biologics, Inc. rEVO Biologics is a trademark of rEVO Biologics, Inc. 2014 rEVO Biologics, Inc.

revobiologics.com

Media Resources | rEVO

http://revobiologics.com/media-resources

For US Residents Only. Message from our President. A major clinical study is well underway at. Watch a video on preeclampsia and the PRESERVE. Preeclampsia affects about 200,000 pregnancies. See the Health Alert news story on a new study. Learn about hereditary antithrombin (AT). REVO Media Relations is available to respond to journalists' inquiries and requests. In addition to providing news releases, we can also often provide:. Background information on our products and technology.

revobiologics.com

Mission and Values | rEVO

http://revobiologics.com/mission-and-values

For US Residents Only. Message from our President. At rEVO Biologics, Inc., our mission is to bring highly innovative, life-saving medicines to patients with under-served and rare diseases. With strength, stability, tenacity and deep experience, rEVO Biologics is delivering on the promise of recombinant technology with revolutionary therapies to address an ever-growing set of unmet medical needs. Message from our President.

revobiologics.com

Publications | rEVO

http://revobiologics.com/publications

For US Residents Only. Message from our President. REVO Biologics, Inc.'s technology and products have been well reported in scientific literature and at scientific meetings. A selected bibliography is below. Selected Publications on Antithrombin and. Paidas M.J., Forsyth C, Quere I, et al ( 2014). Perioperative and peripartum prevention of venous thromboembolism in patients with hereditary antithrombin deficiency using recombinant antithrombin therapy. Blood Coagulation and Fibrinolysis:00;1-7. Edmunds,...

revobiologics.com

News | rEVO

http://revobiologics.com/news

For US Residents Only. Message from our President. Study Reports Significant Increase in Incidence of Preeclampsia, a Potentially Life-threatening Pregnancy Complication. FRAMINGHAM, Mass., Oct. 22, 2015. A study published recently in the American Journal of Perinatology reports a dramatic increase in the incidence of preeclampsia in the United States. Preeclampsia and early onset preeclampsia have grown 67 percent and 140 percent respectively over the past two decades. FRAMINGHAM, Mass., May 14, 2015.

revobiologics.com

Scientific Advisors | rEVO

http://revobiologics.com/scientific-advisors

For US Residents Only. Message from our President. REVO Biologics, Inc. is working with leading researchers from both academia and industry clinicians with expertise in hematology, neonatology, maternal fetal medicine, genetic disorders, as well as DNA technology and recombinant medicine. The company is committed to working collaboratively with the medical community who best understand the challenges associated with tough to treat diseases and conditions.

revobiologics.com

Leadership | rEVO

http://revobiologics.com/leadership

For US Residents Only. Message from our President. REVO Biologics, Inc. is led by a team of business experts and scientists with a successful track record of developing and commercializing important and highly innovative healthcare technologies and life-changing therapeutics. Yann Echelard, Ph.D. Yann Echelard, Ph.D. Senior Vice President, Program Management. Senior Vice President, Program Management. Senior Vice President of Commercial Operations. Senior Vice President of Commercial Operations. Mary Ann...